Figures & data
Table 1. Baseline characteristics of the simulated cohorts.
Table 2. Treatment effects applied in the first year of the analysis.
Table 3. Cost-effectiveness outcomes of the base case analyses.
Figure 1. Mean direct costs associated with liraglutide 1.2 mg and sitagliptin over patient lifetimes. EUR, 2013 Euros.
![Figure 1. Mean direct costs associated with liraglutide 1.2 mg and sitagliptin over patient lifetimes. EUR, 2013 Euros.](/cms/asset/775b7eed-535e-4050-9852-3f0ede7dfbd2/ijme_a_1100998_f0001_c.jpg)
Table 4. Liraglutide vs sitagliptin: Results of the sensitivity analyses.
Figure 2. Liraglutide vs sitagliptin: Cost-effectiveness scatterplot for the probabilistic sensitivity analyses. EUR, 2013 Euros, QALY, quality-adjusted life year.
![Figure 2. Liraglutide vs sitagliptin: Cost-effectiveness scatterplot for the probabilistic sensitivity analyses. EUR, 2013 Euros, QALY, quality-adjusted life year.](/cms/asset/f6e6dbca-fb09-43a7-b07c-9e9d5475d223/ijme_a_1100998_f0002_c.jpg)
Figure 3. Liraglutide vs sitagliptin: Cost-effectiveness acceptability curve for the probabilistic sensitivity analysis. EUR, 2013 Euros; QALY, quality-adjusted life year.
![Figure 3. Liraglutide vs sitagliptin: Cost-effectiveness acceptability curve for the probabilistic sensitivity analysis. EUR, 2013 Euros; QALY, quality-adjusted life year.](/cms/asset/634ac582-fcd5-42ec-b6cb-e63a173b98cb/ijme_a_1100998_f0003_c.jpg)
Figure 4. Mean direct costs associated with liraglutide 1.2 mg and glimepiride over patient lifetimes EUR, 2013 Euros; QALYs, quality-adjusted life years.
![Figure 4. Mean direct costs associated with liraglutide 1.2 mg and glimepiride over patient lifetimes EUR, 2013 Euros; QALYs, quality-adjusted life years.](/cms/asset/24924b2a-6bb3-41d1-b58a-8f8d2f8dffc5/ijme_a_1100998_f0004_c.jpg)
Table 5. Liraglutide vs glimepiride: Results of the sensitivity analyses.
Figure 5. Liraglutide vs glimepiride: Cost-effectiveness scatterplot for the probabilistic sensitivity analyses. EUR, 2013 Euros, QALY, quality-adjusted life year.
![Figure 5. Liraglutide vs glimepiride: Cost-effectiveness scatterplot for the probabilistic sensitivity analyses. EUR, 2013 Euros, QALY, quality-adjusted life year.](/cms/asset/52a6ca40-63b5-4334-a370-fe90e8d723e6/ijme_a_1100998_f0005_c.jpg)
Figure 6. Liraglutide vs glimepiride: Cost-effectiveness acceptability curve for the probabilistic sensitivity analysis. EUR, 2013 Euros; QALY, quality-adjusted life year.
![Figure 6. Liraglutide vs glimepiride: Cost-effectiveness acceptability curve for the probabilistic sensitivity analysis. EUR, 2013 Euros; QALY, quality-adjusted life year.](/cms/asset/dfc2ba64-4860-4f79-8995-7efc6323e0de/ijme_a_1100998_f0006_c.jpg)